ClinicalTrials.gg
CompletedNCT04802733Updated Nov 1, 2024

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

A Phase 1 interventional study of MSK-DA01 and MSK-DA01 Cell Delivery Device in Advanced Parkinson's Disease, sponsored by BlueRock Therapeutics. Completed at 3 sites in 2 countries. Open to participants aged 50 Years to 78 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by BlueRock Therapeutics (part of Bayer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.

Started
2021
the only one that year
Phase 1
Only one
of the 12
Registered
3rd of 12
by date

Among the 12 studies in Parkinson Disease by Bayer, this one is the only one that started in 2021, is the only one in phase 1, and was the 3rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Bayer, or all of them as a file.
02

Study summary

This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

Read the detailed description

Subjects will undergo surgical transplantation of the dopamine-producing cells under general anesthesia into a part of the brain called the putamen. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year. Safety, tolerability, evidence of cell survival (using MRI and PET scans of the brain), and effect on Parkinson's disease symptoms are assessed for 2 years post-transplant.

03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-78 years old (Canada)
  • Age 60-78 years old (United States)
  • Diagnosis of Parkinson's Disease made between 3 to 20 years ago
  • Taking levodopa, but with complications of therapy such as wearing off and/or dyskinesia
  • Able to participate in all study visits and evaluations, including brain MRI and PET scan
  • Existence of a study partner who may act as potential surrogate over long term for ongoing consent

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or other neurodegenerative diseases such as Alzheimer's disease
  • Prior Deep Brain Stimulation , lesion therapy, or gene therapy for PD
  • Prior surgical or radiation therapy to the brain or spinal cord
  • Any medical condition resulting in high risk of drugs, including any active infectious disease
  • Inability to temporarily stop anti- agents or other anti-coagulant medications without serious risk
  • Previous or currently active malignant disease within the past 5 years, except basal cell carcinoma or in situ uterine cervical carcinoma that have been treated
  • Severe obesity (>350 lbs) or any condition that prevents use of PET/MRI
  • Pregnancy or breastfeeding
  • to surgery or general anesthesia
  • In the opinion of the investigator, any other condition regarded as making subject unsuitable for trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    MSK-DA01

    Biological: MSK-DA01 · Device: MSK-DA01 Cell Delivery Device

Interventions

  • BiologicalMSK-DA01

    MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.

  • DeviceMSK-DA01 Cell Delivery Device

    A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    The incidence of Serious Adverse Events (SAEs) at 1 year post-transplant. or abnormal tissue overgrowth related to presence of transplanted cells;

    Time frame: Baseline to 1 Year Post-Transplant

Secondary outcomes

  1. Evidence of Cell Survival

    Change in 18F-DOPA uptake using positron emission tomography (PET) from baseline to 1 and 2 years

    Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant

  2. Changes in Motor Function

    Changes in MDS-Unified Parkinson's Disease Rating Scale (UPDRS) motor sub-score in the "off" state from baseline to 2 years post-transplant.

    Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant

  3. Changes in Waking Hours in "Off" State

    Changes in number of waking hours in the "off" state from baseline to 2 years post-transplant.

    Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant

  4. Continued Safety and Tolerability

    Incidence of SAEs at 2 years post-transplant and incidence and type of AEs at 1 and 2 years post-transplant.

    Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant

07

Study locations

3 sites
  • University of California Irvine
    Orange, California 92868, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2023, 24 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 24 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Mar 17, 2021
StartActual
May 3, 2021
Primary completionActual
May 18, 2023
CompletionActual
Jun 10, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04802733
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
May 3, 2021
Primary completion
May 18, 2023
Completion
Jun 10, 2024
Last update
Nov 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion